TAG:
laboratories
In Medicare Bull’s Eye: Lab Test Reimbursement
By R. Lewis Dark | From the Volume XIX No. 13 – September 17, 2012 Issue
YOU CAN CONSIDER THIS ISSUE OF THE DARK REPORT TO BE an early warning of the escalating effort by public and private payers to rein in the “soaring cost” of clinical laboratory testing and anatomic pathology services. The intelligence briefings you will read on the following pag…
Damon Laboratories, Mitt Romney, and Politics
By R. Lewis Dark | From the Volume XIX No. 12 – August 27, 2012 Issue
IT IS SELDOM THAT THE CLINICAL LABORATORY INDUSTRY HITS THE RADAR SCREEN during a presidential election. So it is with some interest that I report to you that Mitt Romney recently touted the lessons he learned while serving on the board of Damon Clinical Laboratories, Inc., as useful…
Prostate Biopsy Claims Affected by Policy Change
By Joseph Burns | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO SUMMARY: Quietly, with no fanfare and little advance public notice, the Medicare program is taking steps to change reimbursement policy for prostate biopsies. On August 7, 2012, Palmetto GBA adopted the new policy published on January 1, 2012, by the National Correct …
Root Cause Analysis Used To Find Source of Errors
By Joseph Burns | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO SUMMARY: It is a reminder that today’s sophisticated laboratory test systems still have the potential to malfunction in unexpected ways. This spring, following installation and validation of a new chemistry instrument, one Canadian hospital laboratory quickly recognized that a serie…
Narrower Provider Networks Topic during Quest Conference Call
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
SINCE MAY 1, 2012, the nation’s largest clinical laboratory company has had a new CEO, who is Stephen H. Rusckowski. The company’s second quarter conference call provided an opportunity to learn more about how he views Quest Diagnostics Incorporated. Conducted on July 19, the fi…
Pathologists in China, U.S. Linked By Digital Pathology
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…
Leica, Aperio, Myriad, AMP, Hologic, Gen-Probe
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
LEICA BIOSYSTEMS TO ACQUIRE APERIO FOR THE SECOND TIME IN AS MANY YEARS, a global leader in histology systems and products has announced that it will acquire one of the leading digital pathology companies. This time it is Leica Biosystems of Nussloch, German…
August 27, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
How big is the market for laboratory testing in China, with its 20,000 hospitals and population of 1.3 billion people? A new report estimates that the independent clinical laboratory industry in China currently generates about 2 billion Yuan Renminbi per year in revenue. This is equal to about US $31…
Congress May Respond to Tough CLIA PT Penalties
By Joseph Burns | From the Volume XIX No. 11 – August 6, 2012 Issue
CEO SUMMARY: For years, severe penalties in cases where a laboratory has inadvertently erred in handling proficiency testing (PT) specimens have been a point of contention between the Centers for Medicare & Medicaid Services (CMS) and the clinical laboratory profession. Two bills prop…
Existing CLIA Language Drives PT Enforcement
By Joseph Burns | From the Volume XIX No. 11 – August 6, 2012 Issue
CEO SUMMARY: Revocation of a lab’s CLIA license as penalty for inadvertent errors in handling proficiency tests (PT) is not a new problem. As explained here, most clinical laboratories have appropriate protocols for handling PT samples. But, when errors occur, the Centers for Medicare &…
CURRENT ISSUE

Volume XXXII, No. 12 – August 25, 2025
In an exclusive interview, a laboratory industry M&A specialist discusses what’s driving lab outreach sales to national lab companies. Also, The Dark Report analyzes ways in which pathology and clinical labs can profitably partner with pharmaceutical companies.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized